GB201315946D0 - Oncology vaccine - Google Patents

Oncology vaccine

Info

Publication number
GB201315946D0
GB201315946D0 GBGB1315946.2A GB201315946A GB201315946D0 GB 201315946 D0 GB201315946 D0 GB 201315946D0 GB 201315946 A GB201315946 A GB 201315946A GB 201315946 D0 GB201315946 D0 GB 201315946D0
Authority
GB
United Kingdom
Prior art keywords
oncology
vaccine
oncology vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1315946.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altimmune UK Ltd
Original Assignee
Immune Targeting Systems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Targeting Systems Ltd filed Critical Immune Targeting Systems Ltd
Priority to GBGB1315946.2A priority Critical patent/GB201315946D0/en
Publication of GB201315946D0 publication Critical patent/GB201315946D0/en
Priority to US14/916,813 priority patent/US20160199469A1/en
Priority to KR1020167009027A priority patent/KR20160131998A/ko
Priority to AU2014316791A priority patent/AU2014316791A1/en
Priority to MX2016002937A priority patent/MX2016002937A/es
Priority to PCT/GB2014/052675 priority patent/WO2015033140A1/en
Priority to EP14762073.6A priority patent/EP3041493A1/en
Priority to JP2016539635A priority patent/JP2016530290A/ja
Priority to CA2922467A priority patent/CA2922467A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1315946.2A 2013-09-06 2013-09-06 Oncology vaccine Ceased GB201315946D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB1315946.2A GB201315946D0 (en) 2013-09-06 2013-09-06 Oncology vaccine
US14/916,813 US20160199469A1 (en) 2013-09-06 2014-09-04 Oncology vaccine
KR1020167009027A KR20160131998A (ko) 2013-09-06 2014-09-04 종양 백신
AU2014316791A AU2014316791A1 (en) 2013-09-06 2014-09-04 Oncology vaccine
MX2016002937A MX2016002937A (es) 2013-09-06 2014-09-04 Vacuna oncologica.
PCT/GB2014/052675 WO2015033140A1 (en) 2013-09-06 2014-09-04 Oncology vaccine
EP14762073.6A EP3041493A1 (en) 2013-09-06 2014-09-04 Oncology vaccine
JP2016539635A JP2016530290A (ja) 2013-09-06 2014-09-04 腫瘍学ワクチン
CA2922467A CA2922467A1 (en) 2013-09-06 2014-09-04 Oncology vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1315946.2A GB201315946D0 (en) 2013-09-06 2013-09-06 Oncology vaccine

Publications (1)

Publication Number Publication Date
GB201315946D0 true GB201315946D0 (en) 2013-10-23

Family

ID=49486881

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1315946.2A Ceased GB201315946D0 (en) 2013-09-06 2013-09-06 Oncology vaccine

Country Status (9)

Country Link
US (1) US20160199469A1 (https=)
EP (1) EP3041493A1 (https=)
JP (1) JP2016530290A (https=)
KR (1) KR20160131998A (https=)
AU (1) AU2014316791A1 (https=)
CA (1) CA2922467A1 (https=)
GB (1) GB201315946D0 (https=)
MX (1) MX2016002937A (https=)
WO (1) WO2015033140A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2995771A1 (en) 2015-09-25 2017-03-30 Imcyse Sa Improved methods and compounds for eliminating immune responses to therapeutic agents
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520539D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
US11464839B2 (en) 2015-12-04 2022-10-11 Mayo Foundation For Medical Education And Research Methods and vaccines for inducing immune responses to multiple different MHC molecules
EP4253419A3 (en) 2016-06-02 2024-05-22 Ultimovacs ASA A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
SI3573647T1 (sl) * 2017-01-27 2023-07-31 Immatics Biotechnologies Gmbh Peptidi in kombinacija peptidov za uporabo v imunoterapiji proti raku jajčnikov in drugim oblikam raka
CN110651189B (zh) 2017-03-03 2024-10-25 特雷斯生物有限公司 肽疫苗
WO2018187515A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
EP3773710A4 (en) * 2018-04-04 2022-03-16 Altimmune Inc COMBINATIONS OF VACCINE COMPOSITIONS INDUCING T LYMPHOCYTES AND THEIR USES
HRP20230007T1 (hr) * 2018-04-11 2023-03-03 Enterome S.A. Antigenski peptidi, namijenjeni sprječavanju i liječenju raka
CN112912387A (zh) * 2018-08-22 2021-06-04 弗雷德哈钦森癌症研究中心 靶向kras或her2抗原的免疫疗法
GB201814362D0 (en) * 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
JP7642530B2 (ja) 2018-09-04 2025-03-10 トレオス バイオ リミテッド ペプチドワクチン
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
JP7153287B2 (ja) * 2020-05-12 2022-10-14 住友ファーマ株式会社 癌を処置するための医薬組成物
WO2025227519A1 (zh) * 2024-04-29 2025-11-06 北京臻知医学科技有限责任公司 一种肿瘤疫苗及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3560399A (en) * 1998-04-15 1999-11-01 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030224036A1 (en) * 1999-12-13 2003-12-04 Fikes John D Hla class I a2 tumor associated antigen peptides and vaccine compositions
WO2001055393A2 (en) * 2000-01-28 2001-08-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
AUPQ776100A0 (en) * 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
WO2005033278A2 (en) * 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
GB0609121D0 (en) * 2006-05-09 2006-06-21 Univ Birmingham Peptide Therapy
EP3320912B1 (en) * 2008-04-17 2021-03-31 IO BIOTECH ApS Indoleamine 2, 3-dioxygenase based immunotherapy
TW201008574A (en) * 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
GB201019331D0 (en) * 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
JP5883443B2 (ja) * 2010-07-22 2016-03-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規の抗原結合タンパク質
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
US20120328660A1 (en) * 2011-06-03 2012-12-27 Tsuji Takemasa Immunogenic compositions useful in provoking an integrated response to tumor antigens

Also Published As

Publication number Publication date
JP2016530290A (ja) 2016-09-29
US20160199469A1 (en) 2016-07-14
EP3041493A1 (en) 2016-07-13
KR20160131998A (ko) 2016-11-16
MX2016002937A (es) 2016-07-07
WO2015033140A1 (en) 2015-03-12
CA2922467A1 (en) 2015-03-12
AU2014316791A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
IL276210B1 (en) Mers-cov vaccine
DK3689865T3 (en) Hidtil ukendte aminopyrimidinderivater
DK3088517T3 (en) Humant anti-il-33-neutraliserende monoklonalt antistof
DK3736291T3 (en) Anti-FCRH5-antistoffer
DK3354246T3 (en) Udstyrsmonteringssystem
DK3077519T3 (en) Cmv-vacciner
GB201315946D0 (en) Oncology vaccine
DK3470074T3 (en) Probiotika
DK3056208T3 (en) Immunpotentiator
AU353576S (en) Stamphousing
GB201310755D0 (en) Therapy
PL2958935T3 (pl) Szczepionka
DK2979701T3 (en) Antitumormiddel indbefattende irinotecanhydrochloridhydrat
PL2991675T3 (pl) Szczepionka Campylobacter
EP3014557A4 (en) TELEPHONE ON FILE
GB201300001D0 (en) Envirep - environment replicater
DK2989854T3 (en) Strømstyret opvarmningssystem
AU4899P (en) Herbie53 Iresine herbstii
AU4953P (en) Flogazora Gazania rigens
AU4977P (en) Harrosy Gaura lindheimeri
GB201320646D0 (en) Vaccine
GB201315556D0 (en) Vaccine
AU2013099V (en) Little Lorey Chamelaucium floriferum
AU353327S (en) Kettlebell
AU353328S (en) Kettlebell

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)